Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Studying Cancer Individuality by Personal and Predictive Drug Screening and Differential OMICs

Project description

Innovative screening platform for personalised cancer treatment

Successful cancer treatment requires an understanding of the molecular and cellular systems that define response to medication, and the development of specific assays that predict patient responses to treatments. The EU-funded SCIPER project aims to identify the mechanisms creating the drug response variability among cancer patients and develop assays to accurately predict treatment responses of late-stage cancer patients. The project is developing a platform that measures ex vivo drug responses from patient biopsies by immunofluorescence, automated confocal microscopy, single-cell image analysis, and machine learning. The state-of-the-art Pharmacoscopy assay platform combines image-based drug screening of patient biopsies and their molecular profiling and patient data in a series of clinical studies, ensuring the applicability of the technology.

Objective

The cellular and molecular systems that determine drug responses in cancer are complex, highly individual, and incompletely understood. As a result, many cancer patients receive ineffective or even harmful therapies, which endangers lives, burdens healthcare systems, and prevents new therapies from reaching clinical approval.

To address this problem, we are developing a platform that measures hundreds of ex vivo drug responses from small patient biopsies by immunofluorescence, automated confocal microscopy, single-cell image analysis, and machine learning. We preserve cellular memory and maximize physiological relevance by not culturing or sorting cells prior to drug exposure. Sub-cellular, single-cell, and cell population-wide image analysis reveals on-target drug responses and disentangles multicellular ones. In a first interventional clinical trial, this phenotypic information alone led to strongly improved treatment of patients with aggressive hematologic malignancies.

Enabled by this high-throughput, predictive, and phenotypic information, I here propose to identify the molecular and cellular systems that govern treatment response individuality in cancer. (Aim 1) We will combine drug response profiling with RNA sequencing and proteomic measurements of malignant and healthy cells from the same biopsies. Critically, the patient-internal comparisons in both screening and OMICs allow neutralizing complex confounding factors. (Aim 2) New multiplexed immunofluorescence and convolutional neural network-based analyses will identify multiclass cell-types and -states, and quantify non-cell-autonomous responses. (Aim 3) Computational integration and causal inference will identify the molecular determinants and governing principles of drug response individuality in cancer, amenable to further validation. This proposal will thus improve our mechanistic understanding of cancer individuality and develop powerful new tools for OMICs-based precision medicine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-STG - Starting Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-STG

See all projects funded under this call

Host institution

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Net EU contribution
€ 1 500 000,00
Address
Raemistrasse 101
8092 Zuerich
Switzerland
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 500 000,00

Beneficiaries (1)